Neonatal cortical hyperostosis secondary to prolonged use of prostaglandin E1 in a patient with pulmonary atresia

Nazan Neslihan Doğan; Dilek Dilli; Melek Pala Akdoğan; Utku Arman Örün; Hakan Aydın; Ayşegül Zencircioğlu

doi:10.5578/GMJ.27969

Authors

Nazan Neslihan Doğan Clinic of Neonatology, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara
Dilek Dilli Clinic of Neonatology, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara
Melek Pala Akdoğan Clinic of Radiology, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara
Utku Arman Örün Clinic of Pediatric Cardiology, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara
Hakan Aydın Clinic of Cardiovasculary Surgery, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara
Ayşegül Zencircioğlu Clinic of Neonatology, Dr. Sami Ulus Maternity and Children Training and Research Hospital, Ankara

DOI:

https://doi.org/10.5578/GMJ.27969

Keywords:

Prostaglandin E1, cortical hyperostosis, newborn, cyanotic congenital heart disease

Abstract

Pulmonary atresia is a rare congenital cardiac malformation. The newborns with this anomaly are ductus dependent to maintain a continuous and adequate pulmonary blood fl ow. As spontaneous closure of the ductus is expected after few hours or days after birth, the patency of ductus should be provided by prostaglandin E1 (PGE1) while the patient is awaiting cardiosurgical intervention. PGE1 infusion is usually applied for a short time period. However, in some circumstances, the infusion duration may extend from weeks to months. Long term PGE1 infusions may produce several adverse effects. In this report, we presented a case of newborn with pulmonary atresia who developed cortical hyperostosis secondary to prolonged use of PGE1.

Metrics

Metrics Loading ...

References

Keith JD, Rowe RD, Vlad P. In: Keith JD, Rowe RD, Vlad P (eds). Heart diseases in infancy and childhood, 2nd ed. Macmillan New York, 1967;923.

Leonhardt A, Glaser A, Wegmann M. Expression of prostanoid receptors in human ductus arteriosus. Br J Pharmacol 2003;138:655-9.

Elliott RB, Starling MB, Neutze JM. Medical manipulation of the ductus arteriosus. Lancet 1975:1:140-2.

Velaphi S, Cilliers A, Beckh-Arnold E. Cortical hyperostosis in an infant on prolonged prostaglandin infusion: case report and literature review. J Perinatol 2004;24:263-5.

Kosiak W, Swieton D, Fryze I, Aleszewicz-Baranowska J, Duklas M, Chojnicki M. Gastric outlet obstruction due to an iatrogenic cause in a neonatal period-report of two cases. Ultraschall Med 2009;30:401-3.

Vanhaesebrouck S, Allegaert K, Vanhole C. Pseudo-Bartter syndrome in a neonate on prostaglandin infusion. Eur J Pediatr 2003;162:569-71.

Arav-Boger R, Baggett HC, Spevak PJ, Willoughby RE. Leukocytosis caused by prostaglandin E1 in neonates. J Pediatr 2001;138:263-5.

Lewis AB, Freed MD, Heymann MA, Roehl SL, Kensey RC. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease. Circulation 1981;64:893-8.

Tálosi G, Katona M, Túri S. Side-effects of long-term prostaglandin E1 treatment in neonates. Pediatr Int 2007;49:335-40.

Huang FK, Lin CC, Huang TC, Weng KP, Liu PY, Chen YY, et al. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Pediatr Neonatol 2013;54:102-6.

Abdelaziz M, John CM. Hyperostosis: an under-recognized complication of prostaglandin infusion. Acta Pediatr 2013;102:e192.

Shandilya R, Gadre KS, Sharma J, Joshi P. Infantile cortical hyperostosis (Caffey disease): a case report and review of the literature--where are we after 70 years? J Oral Maxillofac Surg 2013;71:1195-201.